Vertex Pharmaceuticals Paris - Search News

News

Vertex Pharmaceuticals Stock Sinks

Investopedia on MSN · 2d

Vertex Pharmaceuticals Stock Sinks as Costs Soar

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 billion, respectively.

The Motley Fool on MSN · 2d

Why Vertex Pharmaceuticals Stock Is Sinking Today

Shares of Vertex Pharmaceuticals ( VRTX -12.76%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Barron's on MSN · 2d

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here’s Why.

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that missed analysts’ expectations and disclosed narrower-than-expected access to its new non-opioid painkiller.

Vertex Abandons AAV as Gene Therapy Space Weathers Difficulties

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

1don MSN

Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss

Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...

3d

Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results